Results 1 to 1 of 1

Thread: The DNA Data We Have Is Too White. Scientists Want to Fix That

  1. #1
    Funding Member Nachtengel's Avatar
    Join Date
    Jul 2008
    Last Online
    @
    Ethnicity
    German
    Gender
    Posts
    5,364
    Thanks Thanks Given 
    12
    Thanks Thanks Received 
    48
    Thanked in
    32 Posts

    The DNA Data We Have Is Too White. Scientists Want to Fix That

    We live in the age of big DNA data. Scientists are eagerly sequencing millions of human genomes in the hopes of gleaning information that will revolutionize health care as we know it, from targeted cancer therapies to personalized drugs that will work according to your own genetic makeup.

    There’s a big problem, however: the data we have is too white. The vast majority of participants in worldwide genomics research are of European descent. This disparity could potentially leave out minorities from benefitting from the windfall of precision medicine. “It’s hard to tailor treatments for people’s unique needs, if the people who are suffering from those diseases aren’t included in the studies,” explains Jacquelyn Taylor, associate professor in nursing who researches health equity at New York University.

    That’s about to change with the “All of Us” initiative, an ambitious health research endeavor by the National Institutes of Health that launches in May. Originally created in 2015 under President Obama as the Precision Medicine Initiative, the project aims to collect data from at least 1 million people of all ages, races, sexual identities, income and education levels. Volunteers will be asked to donate their DNA, complete health surveys and wear fitness and blood pressure trackers to offer clues about the interplay of their stats, their genetics and their environment.

    By embracing—and actively seeking out—more minorities in research, the project hopes to give more accurate data about the overall population and fix a long-time discrepancy that has real health impacts. Case in point: African-Americans have the highest prevalence of hypertension of any other group in the United States—about 45 percent, compared to 33 percent on average for whites, says Taylor. {snip}

    Currently, there are some 50 large-scale genomics research studies around the world that involve at least 100,000 people, according to remarks by NIH Director Francis Collins at the World Economic Forum in Davos, Switzerland earlier this year. Yet an influential 2016 paper in the journal Nature found that 87 percent of participants in worldwide genomics research were of European descent.

    {snip} In order to deliver healthcare recommendations tailored to individuals, researchers need to better understand the biology of your ancestry and ethnicity. If your genetic background isn’t represented in the biobank, you could potentially miss out on certain cures. {snip}.

    “It might be that the Alzheimer’s allele shows up in people of European ancestry, but not as frequently in people of African ancestry or that prostate cancer is unusually aggressive only in people of African descent,” says Eric Topol, director of the Scripps Translational Science Institute and a principal investigator for “All of Us” in San Diego. “But you need to study millions of people to fully understand these associations. The technology is continuing to scale, but that’s not what’s holding us back,” says Topol. “It’s the number and diversity of people.”

    In other words, we need more people who are not of European descent.

    {snip} Most of the non-European representation came from national studies in China, Japan and South Korea. Moreover, that increase in diversity didn’t include other minorities. People of African descent only accounted for 3 percent, and Hispanics weighed in at half a percentage point—despite making up 13 percent and 18 percent of the U.S. population, respectively.

    In addition to developing individualized cures, researchers are hunting for the holy grail that would revolutionize medicine for the masses: key mutations that could shape the development of future drugs. For example, by studying the genetic makeup of people of African ancestry who had very low cholesterol, researchers found they possessed a mutation that kept their levels low and resulted in fewer heart attacks. The discovery led to the newest class of cholesterol medications known as PCSK9 inhibitors.

    {snip}

    Private companies are also aware of the diversity problem. Direct-to consumer genetic sequencing company 23andMe recently received a $1.7 million NIH grant in 2016 to conduct more extensive sequencing of several thousand customers of African-American descent. {snip}

    {snip}

    Lingering Mistrust

    If minority participation is so highly valued in medical research, why are these communities so noticeably absent from studies?

    Experts point to a complex tangle of emotional and practical hurdles. “There’s a history of medical mistreatment that prevents minorities from getting really excited about volunteering,” says Tshaka Cunningham, science advisor for the Minority Coalition for Precision Medicine. {snip} researchers often refer to the enduring legacy of Tuskegee. {snip}

    {snip}

    Similar concerns about lack of consent and privacy provoked the Navajo Nation to outlaw genetic research in 2002, although tribal leaders are currently considering lifting the moratorium to guide the development of new disease treatments.

    Minorities might also be shut out of studies because they didn’t have financial or geographic access to the top-level urban medical centers where researchers traditionally have done most of their recruitment, says Fullerton. {snip}

    That’s why All of Us recruiters are trying to knock on other doors—specifically black churches in Baltimore, Bay Area community centers hosting Spanish-language bingo games and nail salons on Chicago’s south side. That’s in addition to establishing partnerships with Walgreens drugstores, Quest Diagnostics labs and local blood banks to expand access for people in remote areas. “There are new players we’ve brought to the table like federally-funded health centers where the most diverse and disenfranchised groups often get access to health care,” says Eric Dishman, director of All of Us. “We’re going to reach the people left behind.” {snip}

    {snip}

    Fears About Precision Medicine

    The challenge, according to some bioethicists, is that many still hesitate to hand over their genetic data, either to the government or private companies, because they worry it could hurt them later. “For minorities, trust has always been a big issue, but talking about DNA adds a different twist because there are so many nuances about what genetics means,” says Consuelo Wilkins, executive director of the biomedical research alliance between Meharry Medical College and Vanderbilt Medical Center. {snip}

    In Stanford bioethicist David Magnus’ focus groups, he learned that minorities viewed donating genetic material more seriously. “Many people believe that DNA samples were a piece of themselves in a way that other health data were not,” he says. “Some people said, ‘What will they do with it? Could they clone another me?’”

    Their concerns vary, but a few common ones include the possibility of law enforcement using DNA to falsely accuse people of crimes. While DNA evidence has been instrumental in liberating Death Row inmates, there have also been cases of “false positives” in which innocent people were wrongly implicated in murders. Workplace discrimination is another worry. “One woman asked me, ‘If I’m at high risk for Alzheimer’s, could I lose my job?’” says Wilkins. {snip}

    Then there’s the fear that affordable healthcare coverage for people with pre-existing conditions may not be guaranteed—and your genetics can reveal your disease predispositions. {snip}

    They also questioned whether such research would translate into drugs that would help them or only benefit Big Pharma or insurance companies. “People said, ‘Will this produce medicines we can afford? Or am I helping to create ones that I later won’t be able to afford?’” adds Sandra Soo-Jin Lee, a Stanford anthropologist and bioethicist. “People don’t feel like the research results will serve their best interests.” Some people in the focus groups worried their insurance companies could hypothetically charge them higher copays if their DNA revealed they were part of a group that was found to be susceptible to certain diseases.

    {snip}

    It’s not lost on observers that by embracing science to expose our differences at the most detailed level possible, we may be able to usher in a new era of inclusion. “My hope is that as we get deeper into the study of genomics, we’re going to understand how similar we are as human beings,” says Cunningham. “People will realize we’re less a collection of races. Rather we’re a collection of unique genotypes—each of us beautiful in our own way.”
    https://www.amren.com/news/2018/05/t...t-to-fix-that/

  2. The Following User Says Thank You to Nachtengel For This Useful Post:


Similar Threads

  1. Digital data storage in bacteria's DNA
    By Liberator Germaniae in forum Internet, Security, & Privacy
    Replies: 0
    Last Post: Friday, February 23rd, 2007, 10:23 PM
  2. Ancient DNA may be misleading scientists
    By Nordhammer in forum Population Genetics
    Replies: 3
    Last Post: Wednesday, August 18th, 2004, 07:08 AM
  3. Mitochondrial DNA D-loop hypervariable regions: Czech population data
    By Euclides in forum Mitochondrial (mtDNA) Haplogroups
    Replies: 0
    Last Post: Thursday, July 1st, 2004, 03:40 PM
  4. Dads Deliver More Than Just DNA, Scientists Say
    By Frans_Jozef in forum Parenthood & Family
    Replies: 0
    Last Post: Thursday, May 13th, 2004, 06:51 PM

Bookmarks

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •